<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Hum Mol Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Hum. Mol. Genet</journal-id>
<journal-id journal-id-type="publisher-id">hmg</journal-id>
<journal-title-group>
<journal-title>Human Molecular Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0964-6906</issn>
<issn pub-type="epub">1460-2083</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28444183</article-id>
<article-id pub-id-type="pmc">5886271</article-id>
<article-id pub-id-type="doi">10.1093/hmg/ddx148</article-id>
<article-id pub-id-type="publisher-id">ddx148</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Calcium dysregulation and Cdk5-ATM pathway involved in a mouse model of fragile X-associated tremor/ataxia syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Robin</surname>
<given-names>Gaëlle</given-names>
</name>
<xref ref-type="aff" rid="ddx148-aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>López</surname>
<given-names>José R.</given-names>
</name>
<xref ref-type="aff" rid="ddx148-aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Espinal</surname>
<given-names>Glenda M.</given-names>
</name>
<xref ref-type="aff" rid="ddx148-aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hulsizer</surname>
<given-names>Susan</given-names>
</name>
<xref ref-type="aff" rid="ddx148-aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Paul J.</given-names>
</name>
<xref ref-type="aff" rid="ddx148-aff2">2</xref>
<xref ref-type="aff" rid="ddx148-aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pessah</surname>
<given-names>Isaac N.</given-names>
</name>
<xref ref-type="aff" rid="ddx148-aff1">1</xref>
<xref ref-type="aff" rid="ddx148-aff3">3</xref>
<xref ref-type="corresp" rid="ddx148-cor1"></xref>
<!--<email>inpessah@ucdavis.edu</email>-->
</contrib>
</contrib-group>
<aff id="ddx148-aff1">
<label>1</label>Department Molecular Biosciences, School of Veterinary Medicine, Davis, CA, USA</aff>
<aff id="ddx148-aff2">
<label>2</label>Department of Biochemistry and Molecular Medicine, UC Davis, Davis, CA 95616, USA</aff>
<aff id="ddx148-aff3">
<label>3</label>Medical Investigations of Neurodevelopmental Disorders (MIND) Institute, Sacramento, CA 95817, USA</aff>
<author-notes>
<corresp id="ddx148-cor1"><label>*</label>To whom correspondence should be addressed at: Department of Molecular Biosciences, UC Davis, 1089 Veterinary Medicine Way, 1020 VM3B, Davis, CA 95616, USA. Tel: +1 530 7526696; Fax: +15307527690; Email: <email>inpessah@ucdavis.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>15</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date iso-8601-date="2017-04-21" pub-type="epub">
<day>21</day>
<month>4</month>
<year>2017</year>
</pub-date>
<volume>26</volume>
<issue>14</issue>
<fpage>2649</fpage>
<lpage>2666</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>2</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>6</day>
<month>4</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>4</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com</copyright-statement>
<copyright-year>2017</copyright-year>
</permissions>
<self-uri xlink:href="ddx148.pdf"></self-uri>
<abstract>
<title>Abstract</title>
<p>Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurological disorder that affects premutation carriers with 55-200 CGG-expansion repeats (preCGG) in <italic>FMR1</italic>, presenting with early alterations in neuronal network formation and function that precede neurodegeneration. Whether intranuclear inclusions containing DNA damage response (DDR) proteins are causally linked to abnormal synaptic function, neuronal growth and survival are unknown. In a mouse that harbors a premutation CGG expansion (preCGG), cortical and hippocampal FMRP expression is moderately reduced from birth through adulthood, with greater FMRP reductions in the soma than in the neurite, despite several-fold elevation of <italic>Fmr1</italic> mRNA levels. Resting cytoplasmic calcium concentration ([Ca<sup>2+</sup>]<sub>i</sub>) in cultured preCGG hippocampal neurons is chronically elevated, 3-fold compared to <italic>Wt</italic>; elevated ROS and abnormal glutamatergic responses are detected at 14 DIV. Elevated µ-calpain activity and a higher p25/p35 ratio in the cortex of preCGG young adult mice indicate abnormal Cdk5 regulation. In support, the Cdk5 substrate, ATM, is upregulated by 1.5- to 2-fold at P<sub>0</sub> and 6 months in preCGG brain, as is p-Ser<sup>1981</sup>-ATM. Bax:Bcl-2 is 30% higher in preCGG brain, indicating a greater vulnerability to apoptotic activation. Elevated [Ca<sup>2+</sup>]<sub>i</sub>, ROS, and DDR signals are normalized with dantrolene. Chronic [Ca<sup>2+</sup>]<sub>i</sub> dysregulation amplifies Cdk5-ATM signaling, possibly linking impaired glutamatergic signaling and DDR to neurodegeneration in preCGG brain.</p>
</abstract>
<funding-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">National Institutes of Health</named-content>
<named-content content-type="funder-identifier">10.13039/100000002</named-content>
</funding-source>
<award-id>R01 ES014901, P01 ES011269</award-id>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">IDDRC</named-content>
<named-content content-type="funder-identifier">10.13039/100007857</named-content>
</funding-source>
<award-id>U54HD079125, DoD PR120921</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="18"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>